CSL (ASX:CSL) Change In Receivables : A$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is CSL Change In Receivables?

CSL's change in receivables for the quarter that ended in Dec. 2023 was A$0 Mil. It means CSL's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

CSL's change in receivables for the fiscal year that ended in Jun. 2023 was A$0 Mil. It means CSL's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

CSL's Accounts Receivable for the quarter that ended in Dec. 2023 was A$5,189 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. CSL's Days Sales Outstanding for the six months ended in Dec. 2023 was 81.22.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CSL's liquidation value for the six months ended in Dec. 2023 was A$-17,535 Mil.

CSL Change In Receivables Historical Data

The historical data trend for CSL's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Change In Receivables Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

CSL Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0 Mil.

CSL (ASX:CSL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CSL's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5188.662	/	11659.176	*	91
=	81.22

2. In Ben Graham's calculation of liquidation value, CSL's accounts receivable are only considered to be worth 75% of book value:

CSL's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1519.398	-	27104.148	+	0.75 * 5188.662	+	0.5 * 8315.604
=	-17,535

CSL Change In Receivables Related Terms

Thank you for viewing the detailed overview of CSL's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (ASX:CSL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CMXHF:USA CSJ:Germany

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.